依维莫司联合化疗或靶向药物治疗晚期非小细胞肺癌的临床疗效和安全性  

Efficacy and safety of combination therapy with everolimus in treatment of patients with advanced non-small cell lung cancer

作　　者：崔月倩 胡毅[1] 

机构地区：[1]中国人民解放军总医院肿瘤内一科,北京100853

出　　处：《现代肿瘤医学》2016年第24期3920-3923,共4页Journal of Modern Oncology

基　　金：军队"十二五"项目(编号:CWS12J120)

摘　　要：目的:探索依维莫司联合化疗或靶向药物在二线及多线晚期非小细胞肺癌(non-small-cell lung cancer,NSCLC)中的疗效和安全性。方法:回顾性分析我院2014年1月至2015年12月25例IV期NSCLC患者,二线及多线治疗时应用依维莫司5mg/d联合化疗或靶向药物,观察临床疗效和不良反应。首要观察终点是3个月时的疾病控制率,次要观察指标是无进展生存期。结果:患者中部分缓解1例(4.8%),疾病稳定14例(66.7%),疾病进展6例(28.6%),总体疾病控制率为71.4%,其中3个月时疾病稳定13例,3个月时疾病控制率62%;中位无进展生存期3.2个月。4例出现Ⅲ/Ⅳ级不良反应,表现为口腔黏膜炎、间质性肺炎和腹泻。结论:依维莫司联合化疗或靶向药物用于二线或多线治疗晚期NSCLC能够控制疾病进展,耐受性良好。Objective：To explore the clinical efficacy and adverse events of everolimus combined with chemotherapy and targeted therapy treated in patients with advanced NSCLC who underwent failed first - line therapy. Methods：All 25 advanced NSCLC patients who underwent everolimus combined with targeted therapy or chemotherapy in our hospital from January 2014 to December 2015 were retrospectively analyzed to assess efficacy and toxicity. The primary endpoint of the study was disease control rate at three mounth,the secondary endpoint was progression - free survival. Results：Of the 25 patients,partial response was found in 1 case（4. 8% ）,stable disease was found in 14 cases （66. 7% ）and progressive disease in 6 cases（28. 6% ）,resulting a disease control rate of 71. 4% . At 3 months there were 13 cases in stable stage,the 3 month DCR was 62% . The median progression - free survival was 3. 2 months. The main grade Ⅲ/ Ⅳ toxicity was stomatitis,diarrhea and interstitial pneumonia. Conclusion：Everolimus combined with targeted therapy or chemotherapy shows good objective responses and well tolerance in advanced NSCLC patients undergoing second - line therapy.

关 键 词：非小细胞肺癌 依维莫司 化疗 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]